Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

As reported by Business News

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Business News ↗

Market Samachar is a news aggregator. This article was originally published by Business News. Tap the button above to read the full story on their site.

INDIAN Oil Drops Below $100 as Iran Diplomacy, Hormuz Flows Stunt Rally mint - markets
INDIAN Top stocks to buy today: Eternal, Urban Company, Rain Industries by Vaishali Parekh | Targets, stop-loss mint - markets
INDIAN AMD joins $1 trillion club as shares surge over 180% in 2026 — what’s driving the chipmaker’s massive rally? mint - markets
INDIAN Mastercard to exit Pine Labs in $93 million block deal mint - markets
INDIAN Top stocks to buy today: Eternal, NTPC Green, Kaynes Tech, Aavas, GESHIP by Sumeet Bagadia | target price, stop-loss mint - markets
INDIAN Top stocks in focus today: Investors must watch Pine Labs, Waaree Energies, GRSE shares on Tue, 22 Sept | Triggers mint - markets
INDIAN Stock Market prediction today: Sensex, Nifty outlook for Tue | Kospi, Taiwan Index, Nikkei cues to watch | 22 Sept mint - markets
INDIAN SP Group bonds offered at premium on Tata Sons stake-sale plan: Report Share Market Today

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

More from Market Samachar